Table 4.
Evaluation of Changes in VEGF and Inflammatory Cytokines As Biomarkers of Bevacizumab Activity and Predictors of Clinical Response
| Biomarker | Baseline (ng/mL) |
Change From Baseline to Best Clinical Response (ng/mL) |
P* | Change in Responders (ng/mL) |
Change in Nonresponders (ng/mL) |
P† | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | Median | IQR | Median | IQR | |||
| VEGF | 429 | 282-881 | 186 | 396–−286 | .42 | 290 | 396-134 | 21.8 | 325-−286 | .63 |
| IL-1b | 0.35 | 0.1-0.7 | 0 | 0–−0.2 | .37 | 0.1 | 0.8-0 | −0.1 | 0-−0.2 | .14 |
| IL-6 | 1.6 | 0.9-2.8 | 0 | 0.4-−1.8 | .34 | 0.5 | 0.6-0.4 | −0.4 | 0.1-−1.8 | .11 |
| IL-8 | 44.9 | 22-117 | −11.2 | −2.1-−68.5 | .0023 | −43 | −16.4-−44.2 | −9 | 0.2-−68.5 | .29 |
| IL-10 | 4.6 | 2.6-8.7 | −0.3 | 1.1-−3.4 | .40 | 0.3 | 2.8-−3.3 | −0.8 | 0.3-−3.4 | .58 |
| IL-12p70 | 0.5 | 0.3-0.8 | 0 | 0.6-−0.1 | .35 | 0.6 | 2-−0.2 | 0 | 0.1-0 | .68 |
| IFN-γ | 1 | 0.5-1.9 | 0.3 | 2.9-−0.4 | .13 | 2.9 | 4.7-0 | 0.2- | 1-−0.4 | .52 |
| TNF-α | 10.4 | 7.3-15.6 | −1.8 | 0.9-−6 | .13 | −3 | 0.2-−5.7 | −0.7 | 1.2-−6 | .63 |
Abbreviations: IFN, interferon; IL, interleukin; IQR, interquartile range; VEGF, vascular endothelial growth factor.
*
Nonparametric analysis of change in biomarker (baseline–best clinical response) performed using Wilcoxon signed rank test.
†
Association of change in biomarker (baseline–best clinical response) according to those with or without a major clinical response performed using an exact Wilcoxon rank sum test.